The European Commission approval was based on results showing the immunotherapy regimen improved event-free survival in a Phase III trial.

The firm announced deals with UMass Chan Medical School and Quiver to further its ambitions to develop transformative treatments for the condition.

The treatment has been used in a trial to treat children with GM1 gangliosidosis, but if the FDA allows, this would be the ...

The baby boy with a rare urea cycle disorder received the bespoke therapy within a few months of birth and is doing well, ...

The baby boy received the bespoke therapy within a few months of birth and is doing well, according to a presentation at ASGCT.

The trial aims to enroll 40 patients with FGFR alterations across the US, who won't need to travel far to receive care.

The study tests the autologous CAR T-cell therapy LEU011 in patients who express NGK2DL in at least 10 percent of tumor cells.

The firm is prioritizing development of its anti-DKK1 antibody sirexatamab following promising Phase II results in microsatellite-stable colorectal cancer.

The firm must deprioritize a mitochondrial disease program in order to fast-track PBGENE-DMD to a Phase I study.

Based on promising preclinical data, researchers hope to begin clinically testing PLK1-targeted treatments in young people with fibrolamellar carcinoma.

Having established improved cancer detection, the interval cancer rate will reveal whether AI catches certain early cancers missed by standard screening.

NEW YORK – Erasca said on Tuesday it is prioritizing development of its recently acquired preclinical RAS programs, pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001, and will be ...